A Study on the efficacy and safety of Docetaxel plus Nedaplatin in patients with advanced non-small-cell lung cancer

A Study on the efficacy and safety of Docetaxel plus Nedaplatin in patients with advanced non-small-cell lung cancer - A Study on the efficacy and safety of Docetaxel plus Nedaplatin in patients with advanced non-small-cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005031

Enrollment

Registered

2011-02-05

Start date

2004-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer

Interventions

Docetaxel (60mg/m2) (day 1)+ Nedaplatin (80mg/m2) (day 1) q3-4weeks, 2-4 cycles

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically determined non-small cell lung cancer 2. Measurable tumor sites 3. Clinical stage, IIIB or IV 4. Neither previous cancer therapy ( operation, chemotherapy and radiotherapy) 5. Aged 20-79 years old 6. ECOG performance status 0 or 1 7. Adequate organ functions 8. Life expectancy more than 3 months 9. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Allergy against polysorbert 80 or platinum-containing drugs 2. Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infarction within 6 months, liver cirrhosis, uncontrolled diabetes,hemorrhagic tendency ) 3. Active infections 4. Massive pleural or pericardial effusion 5. Brain metastases with neurological symptoms. 6. Active simultaneous cancer 7. Active interstitial pneumonitis or its past history 8. Peripheral nerve disorder 9. Pregnant or lactating women 10. Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Secondary

Measure	Time frame
Satety	—

Countries

Japan

Contacts

Public ContactKoji Teramoto

Shiga University of Medical Science Department of Surgery

teramoto@belle.shiga-med.ac.jp077-548-2244

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026